NanoPhytomedicine: Harnessing Nature and Nanotechnology for Neurological and Metabolic Health combines the healing potential of bioactive compounds derived from plants with advanced nanoscale delivery systems to highlight the emerging convergence of phytomedicine and nanotechnology in the development of innovative therapeutic strategies for neurological and metabolic disorders.
The book highlights new approaches for addressing some of the most pressing health challenges, including depression, anxiety, obesity, diabetes, and metabolic syndrome. Emphasising the limitations of conventional therapies, the volume presents nano-enabled phytomedicine as a promising avenue for improving treatment efficacy, bioavailability, and patient outcomes. Various nanoscale delivery platforms, including liposomes, polymeric nanoparticles, and nanostructured lipid carriers, are discussed in detail, demonstrating their ability to enhance targeted delivery and minimise adverse effects. Particular attention is given to the complex and bidirectional relationship between mental health and metabolic disorders, highlighting the potential of nano-enhanced natural products as dual-action therapeutic solutions.
Supported by case studies and recent advances in research, the book showcases successful applications of nanophytomedicine, including curcumin-loaded nanoparticles for cognitive enhancement and resveratrol-based nanodelivery systems for the management of metabolic disorders. By integrating traditional natural medicine with modern nanotechnology, the volume offers valuable insights into the development of safer, more effective, and personalised therapeutic approaches.
Key Features
Covers integration of phytomedicine and nanotechnology for neurological and metabolic health, with discussion of the limitations of conventional therapies and the advantages of nano-enabled delivery systems
Explores the interplay between mental health disorders and metabolic diseases
Emphasis on targeted delivery, improved bioavailability, enhanced stability, and reduced side effects
Includes case studies and recent advances in nanophytomedicine research.
Readership
Researchers, academics, clinicians, pharmaceutical scientists, and industry professionals working or interested in the development of next-generation therapies for neurological and metabolic disorders
